Analysts at Leerink Partnrs issued their FY2024 earnings per share estimates for shares of Atyr PHARMA in a research report issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid ...
3d
Hosted on MSNLeerink Partners Initiates Coverage of aTyr Pharma (ATYR) with Outperform RecommendationFintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...
Leerink Partners assumed coverage on shares of Atyr PHARMA (NASDAQ:ATYR – Get Free Report) in a research note issued to ...
Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...
Leerink Partners analyst Faisal Khurshid initiated coverage on aTyr Pharma Inc ATYR with an Outperform rating and announced a ...
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, aTyr Pharma (NASDAQ:ATYR) shareholders have done very well over the last year, with the share ...
In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on aTyr Pharma (ATYR – Research Report), with a price target ...
Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a Outperform recommendation. As of January 29, 2025, the average one-year price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results